leisure time -WSS

leisure time

author：fashion 2025-10-01 11:47:12 - browse：8963

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Asahi Kasei to buy Calliditas, picking up kidney disease drug

WSS

Researchers use wearables data and AI to predict preterm birth risk

Researchers use wearables data and AI to predict preterm birth risk

Hospitals need to get ahead of regulations on climate change

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Data show record exodus of life scientists from academia

focus

leisure time

entertainment

In age of alternative facts, a scholarly course on calling out crap

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

After affirmative action ruling, medical educators look to 'holistic review'

How one patient went off dialysis — and others can too

Psychedelics group wrestles with new pharma identity

Unmasking the 'centricity' illusion in clinical trials

Medicare details structure of new drug price negotiation program

Kaiser Permanente unions announce official strike date

Alkermes shareholders re

Mindstrong's demise and the future of mental health care

hotspot

Decentralized clinical trials need collaboration to achieve wider use

Louisiana bill approved classifying abortion pills as controlled substances

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Decentralized clinical trials need collaboration to achieve wider use

Menendez indictment could see pharma lose a key ally

Why we need mandatory labeling of GMO products

entertainment

focus

focus

focus